Navigation Links
Diverse Coalition of Purchasers Respond to BIO CEO Fly-In: There is Another Side to The Story
Date:4/16/2008

timely resolution to patent disputes and

prohibits frivolous suits that restrict access to biogenerics and

delay competition in the marketplace.

6. Creates a balanced process that encourages innovation by both brand

and generic companies and expands access to prescription medications

for consumers.

7. Does not create a system of endless monopoly pricing and no

opportunity for competition to enter the marketplace.

The following is the text of the latest CCPM ad:

What If Patients Had Wings?

Executives from the multi-billion dollar pharmaceutical and biotech

industry are descending on Congress...flying to Washington to make sure

their monopolies are protected.

Meanwhile countless Americans are struggling to pay for high-priced

biopharmaceutical medicines.

These patients can't fly to Washington on their own, but they are making

their voices heard.

Numerous organizations representing patients, seniors, consumers, labor,

and businesses support legislation to establish a workable approval

pathway for biogenerics.

Americans need balanced legislation that fosters innovation without

excessive market exclusivity which does nothing more than extend

monopolies, stifle competition and keep patients waiting for affordable

medicines.

BIO and PhRMA say that want a biogenerics pathway, but their policy is an

empty promise to patients.

CCPM supports public policies that facilitate timely access to affordable pharmaceuticals. Visit http://www.competitiverx.com for more information and a list of CCPM members.

Contact: Katie Braden Huffard, 202-255-5216;

Andrea Hofelich, 703-647-2495; Charles Cote, 202-207-3605


'/>"/>
SOURCE The Coalition for a Competitive Pharmaceutical Market(CCPM)
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Childhood Influenza Immunization Coalition Applauds Expanded Influenza Vaccine Recommendation for Children
2. FrontPath Health Coalition To Lead Community-wide Group in Pilot Program
3. Coalition for a Competitive Pharmaceutical Market Launches New Print Ad Campaign Highlighting Need for Meaningful Biogenerics Legislation
4. Addressing the Pharmacist Shortage: Medco Labor Coalition(TM) Launches National Scholarship Program to Support the Development of the Next Generation of Pharmacists
5. Agendia Joins the Personalized Medicine Coalition (PMC)
6. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
7. MichBio Responds to Governors Plan to Repeal Tort Reform Laws
8. CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases
9. Bio-Identical Hormone Menopause Doctor Responds to Recent FDA News About Estriol
10. Bio-Identical Hormone Menopause Doctor Responds to Outrageous FDA News
11. CryoLife Responds to Inaccurate Assertions from Plaintiffs Attorney
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014 The report expects global ... by 2019. It also provides a carefully analyzed data ... challenges for the market. , Full Copy of Report ... the global market for cell expansion will keep witnessing ... expects this growth to be driven by rapid technological ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 23, 2014 /PRNewswire/ ... solutions company focused on gynecologic disease, announced today ... W. Schuler , Birchview Fund LLC and several ... million of unregistered shares of Vermillion,s common stock ... common stock in a private placement.  ...
(Date:12/24/2014)... Fla. , Dec. 23, 2014  Rock Creek ... that it has filed a Clinical Trial Application (CTA) ... Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to ... lead molecule, Anatabine Citrate. Contingent on the ... conduct a Phase I trial to assess the safety, ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... 16 BioEnergy International, ... of next-generation, renewable biochemicals and biofuels, announces the ... all of its biobased chemicals business and intellectual ... biofuels opportunities, including its 110 million gallon per ...
... June 16 Wyeth (NYSE: WYE ) (the ... Senior Debentures due 2024 (the "Convertible Debentures") have the right ... to their terms effective on the July 15, 2009 purchase ... in aggregate principal amount of Convertible Debentures outstanding. , ...
... Wound Care Innovations, LLC, a subsidiary of Wound ... reached an agreement in principle to acquire BioPharma Management ... platform of proprietary and patented technologies for topical pain ... structured as a share exchange pursuant to which BioPharma ...
Cached Biology Technology:BioEnergy International, LLC Announces Formation of Myriant Technologies LLC 2Wyeth Announces Holder Right to Surrender Convertible Debentures 2Wyeth Announces Holder Right to Surrender Convertible Debentures 3Wyeth Announces Holder Right to Surrender Convertible Debentures 4Wound Management Technologies, Inc. Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies, Inc. 2
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... of the "Micro Market Monitor: North America Perimeter ... http://photos.prnewswire.com/prnh/20130307/600769 The ... at a CAGR of 3.6% from 2014 to 2019. ... this market, Canada is expected ...
(Date:12/17/2014)... , Dec. 15, 2014 Research and ... the addition of the "Samsung Galaxy S5 ... report to their offering. ... a totally different sensing technology than the iPhone ... fingerprint sensor in its product. The ...
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ... robust – with the clinical data to back it ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... recent study led by scientists from the National University of ... Spinal Muscular Atrophy (SMA), a devastating disease that is the ... young adults. As there is currently no known cure for ... fight against SMA. SMA is caused by deficiencies ...
... , Dec. 18, 2013 Tissue engineering ... a regenerative or reparative medicine with potential to ... engineering, which involve leveraging technologies from biomaterials, molecular ... the restructure and/or repair of human organs through ...
... have shown for the first time that the specialised role ... cilia tiny hair-like structures protruding from a cell. Stem ... body through the process of differentiation. The discovery ... therapies for a range of medical treatments where scientists aim ...
Cached Biology News:Study led by NUS scientists provides new insights into cause of human neurodegenerative disease 2Study led by NUS scientists provides new insights into cause of human neurodegenerative disease 3State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption 2State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption 3State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption 4
...
... CryoMed Freezers for IVF are designed for ... control, ease of setup and operation, and ... status are continuously displayed on the control ... data are printed by way of the ...
... performance for all vacuum requirements. A 3 ... to suit all applications. The large, sideview ... proper oil levels at a glance. The ... work with all Thermo Savant SpeedVac concentrating ...
A powerful, easy-to-use solution, the SORVALL RC12BP Blood Processing System allows you to manufacture blood components quickly and cost-effectively while ensuring product quality, safety, and GMP co...
Biology Products: